You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMesoridazine
Accession NumberDB00933  (APRD00610)
TypeSmall Molecule
GroupsApproved
DescriptionA phenothiazine antipsychotic with effects similar to chlorpromazine. [PubChem]
Structure
Thumb
Synonyms
10-(2-(1-Methyl-2-piperidyl)ethyl)-2-methylsulfinyl phenothiazine
10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine
2-Methanesulfinyl-10-[2-(1-methyl-piperidin-2-yl)-ethyl]-10H-phenothiazine
Mesoridazina
Mesoridazine
Mesoridazinum
Thioridazine Thiomethyl Sulfoxide
thioridazine-2-sulfoxide
TPS-23
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Serentil Tab 10mgtablet10 mgoralNovartis Pharmaceuticals Canada Inc1970-12-312000-08-02Canada
Serentil Tab 25mgtablet25 mgoralNovartis Pharmaceuticals Canada Inc1997-08-292001-07-30Canada
Serentil Tab 50mgtablet50 mgoralNovartis Pharmaceuticals Canada Inc1997-08-292001-07-30Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LidanarNot Available
LidanilNot Available
SerentilNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Mesoridazine besylate
ThumbNot applicableDBSALT001396
Mesoridazine mesilate
ThumbNot applicableDBSALT001073
Categories
UNII5XE4NWM740
CAS number5588-33-0
WeightAverage: 386.574
Monoisotopic: 386.148654844
Chemical FormulaC21H26N2OS2
InChI KeyInChIKey=SLVMESMUVMCQIY-UHFFFAOYSA-N
InChI
InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3
IUPAC Name
2-methanesulfinyl-10-[2-(1-methylpiperidin-2-yl)ethyl]-10H-phenothiazine
SMILES
CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • Benzenoid
  • Piperidine
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Sulfoxide
  • Azacycle
  • Sulfinyl compound
  • Thioether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed in the treatment of schizophrenia, organic brain disorders, alcoholism and psychoneuroses.
PharmacodynamicsMesoridazine, the besylate salt of a metabolite of thioridazine, is a phenothiazine tranquilizer. Pharmacological studies in laboratory animals have established that mesoridazine has a spectrum of pharmacodynamic actions typical of a major tranquilizer. In common with other tranquilizers it inhibits spontaneous motor activity in mice, prolongs thiopental and hexobarbital sleeping time in mice and produces spindles and block of arousal reaction in the EEG of rabbits. It is effective in blocking spinal reflexes in the cut and antagonizes d-amphetamine excitation and toxicity in grouped mice. It shows a moderate adrenergic blocking activity in vitro and in vivo and antagonizes 5-hydroxytryptamine in vivo. Intravenously administered, it lowers the blood pressure of anesthetized dogs. It has a weak antiacetylcholine effect in vitro.
Mechanism of actionBased upon animal studies, mesoridazine, as with other phenothiazines, acts indirectly on reticular formation, whereby neuronal activity into reticular formation is reduced without affecting its intrinsic ability to activate the cerebral cortex. In addition, the phenothiazines exhibit at least part of their activities through depression of hypothalamic centers. Neurochemically, the phenothiazines are thought to exert their effects by a central adrenergic blocking action.
Related Articles
AbsorptionWell absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein binding4%
MetabolismNot Available
Route of eliminationNot Available
Half life24 to 48 hours
ClearanceNot Available
ToxicityOral LD50 is 560 ± 62.5 mg/kg and 644 ± 48 mg/kg in mouse and rat, respectively. Symptoms of overdose may include emesis, muscle tremors, decreased food intake and death associated with aspiration of oral-gastric contents into the respiratory system.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9322
Blood Brain Barrier+0.9863
Caco-2 permeable+0.5609
P-glycoprotein substrateSubstrate0.7284
P-glycoprotein inhibitor IInhibitor0.8978
P-glycoprotein inhibitor IIInhibitor0.5334
Renal organic cation transporterInhibitor0.7467
CYP450 2C9 substrateNon-substrate0.7962
CYP450 2D6 substrateNon-substrate0.5465
CYP450 3A4 substrateSubstrate0.5561
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5635
Ames testNon AMES toxic0.6982
CarcinogenicityNon-carcinogens0.8829
BiodegradationNot ready biodegradable0.9954
Rat acute toxicity2.7465 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7565
hERG inhibition (predictor II)Inhibitor0.762
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg
Tabletoral25 mg
Tabletoral50 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0767 mg/mLALOGPS
logP3.83ALOGPS
logP3.57ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)19.36ChemAxon
pKa (Strongest Basic)8.19ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area23.55 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity115.13 m3·mol-1ChemAxon
Polarizability43.83 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0002-9331000000-8e14cb597ee411174c3eView in MoNA
References
Synthesis Reference

DrugSyn.org

US3084161
General ReferencesNot Available
External Links
ATC CodesN05AC03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineMesoridazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineMesoridazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Mesoridazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Mesoridazine is combined with 7-Nitroindazole.
AbirateroneThe metabolism of Mesoridazine can be decreased when combined with Abiraterone.
AcebutololMesoridazine may increase the hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Mesoridazine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Alfaxalone.
AlfentanilMesoridazine may increase the hypotensive activities of Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Mesoridazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Mesoridazine.
AlphacetylmethadolMesoridazine may increase the hypotensive activities of Alphacetylmethadol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Mesoridazine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Mesoridazine.
AlprenololMesoridazine may increase the hypotensive activities of Alprenolol.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmiodaroneThe metabolism of Mesoridazine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Mesoridazine.
AmobarbitalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amobarbital.
AmodiaquineThe serum concentration of Mesoridazine can be increased when it is combined with Amodiaquine.
AmoxapineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amperozide.
AmphetamineMesoridazine may decrease the stimulatory activities of Amphetamine.
AripiprazoleThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Aripiprazole.
ArotinololMesoridazine may increase the hypotensive activities of Arotinolol.
ArtemetherThe serum concentration of Mesoridazine can be increased when it is combined with Artemether.
ArtesunateThe serum concentration of Mesoridazine can be increased when it is combined with Artesunate.
ArticaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Asenapine.
AtenololMesoridazine may increase the hypotensive activities of Atenolol.
AtomoxetineThe metabolism of Mesoridazine can be decreased when combined with Atomoxetine.
AtovaquoneThe serum concentration of Mesoridazine can be increased when it is combined with Atovaquone.
AzaperoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Azaperone.
AzelastineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Mesoridazine.
BaclofenThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Barbital.
BefunololMesoridazine may increase the hypotensive activities of Befunolol.
BenzocaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Benzocaine.
BenzphetamineMesoridazine may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Benzyl alcohol.
BetaxololMesoridazine may increase the hypotensive activities of Betaxolol.
BetaxololThe metabolism of Mesoridazine can be decreased when combined with Betaxolol.
BevantololMesoridazine may increase the hypotensive activities of Bevantolol.
BezitramideMesoridazine may increase the hypotensive activities of Bezitramide.
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
BisoprololMesoridazine may increase the hypotensive activities of Bisoprolol.
BopindololMesoridazine may increase the hypotensive activities of Bopindolol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.
BrimonidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Mesoridazine.
BrompheniramineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Brotizolam.
BufuralolMesoridazine may increase the hypotensive activities of Bufuralol.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Mesoridazine.
BupranololMesoridazine may increase the hypotensive activities of Bupranolol.
BuprenorphineMesoridazine may increase the hypotensive activities of Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Mesoridazine.
BupropionThe metabolism of Mesoridazine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Mesoridazine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Mesoridazine.
ButacaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Butethal.
ButorphanolMesoridazine may increase the hypotensive activities of Butorphanol.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mesoridazine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Mesoridazine.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Mesoridazine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Carbinoxamine.
CarfentanilMesoridazine may increase the hypotensive activities of Carfentanil.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Mesoridazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Carisoprodol.
CarteololMesoridazine may increase the hypotensive activities of Carteolol.
CarvedilolMesoridazine may increase the hypotensive activities of Carvedilol.
CelecoxibThe metabolism of Mesoridazine can be decreased when combined with Celecoxib.
CeliprololMesoridazine may increase the hypotensive activities of Celiprolol.
CetirizineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Mesoridazine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chloroprocaine.
ChloroquineThe serum concentration of Mesoridazine can be increased when it is combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chlorphenamine.
ChlorphentermineMesoridazine may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe metabolism of Mesoridazine can be decreased when combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Mesoridazine can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Mesoridazine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Mesoridazine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Mesoridazine.
CitalopramThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Citalopram.
ClemastineThe metabolism of Mesoridazine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clidinium.
ClobazamThe metabolism of Mesoridazine can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Mesoridazine is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Mesoridazine.
ClotrimazoleThe metabolism of Mesoridazine can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Mesoridazine can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clozapine.
CobicistatThe serum concentration of Mesoridazine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Mesoridazine.
CodeineMesoridazine may increase the hypotensive activities of Codeine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Mesoridazine.
CyclizineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mesoridazine.
CyproheptadineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Mesoridazine.
DapoxetineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dapoxetine.
DapsoneThe serum concentration of Mesoridazine can be increased when it is combined with Dapsone.
DarifenacinThe metabolism of Mesoridazine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Mesoridazine can be increased when it is combined with Darunavir.
DelavirdineThe metabolism of Mesoridazine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Mesoridazine.
DesloratadineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Mesoridazine.
DetomidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mesoridazine.
DextroamphetamineMesoridazine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Mesoridazine.
DextromoramideMesoridazine may increase the hypotensive activities of Dextromoramide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Mesoridazine.
DextropropoxypheneMesoridazine may increase the hypotensive activities of Dextropropoxyphene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Mesoridazine.
DezocineMesoridazine may increase the hypotensive activities of Dezocine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Mesoridazine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Mesoridazine.
DifenoxinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Difenoxin.
DihydrocodeineMesoridazine may increase the hypotensive activities of Dihydrocodeine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mesoridazine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Mesoridazine.
DihydroetorphineMesoridazine may increase the hypotensive activities of Dihydroetorphine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Mesoridazine.
DihydromorphineMesoridazine may increase the hypotensive activities of Dihydromorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Mesoridazine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Mesoridazine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Diphenhydramine.
DiphenoxylateMesoridazine may increase the hypotensive activities of Diphenoxylate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Mesoridazine.
DoramectinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Mesoridazine.
DoxycyclineThe serum concentration of Mesoridazine can be increased when it is combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.
DoxylamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Doxylamine.
DPDPEMesoridazine may increase the hypotensive activities of DPDPE.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Mesoridazine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.
DronedaroneThe metabolism of Mesoridazine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Mesoridazine.
DrotebanolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Drotebanol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Mesoridazine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Mesoridazine.
EcgonineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Mesoridazine is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Mesoridazine.
EliglustatThe metabolism of Mesoridazine can be decreased when combined with Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Mesoridazine.
EntacaponeThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Entacapone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Mesoridazine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Mesoridazine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Mesoridazine.
EscitalopramThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Escitalopram.
EsmololMesoridazine may increase the hypotensive activities of Esmolol.
EstazolamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Mesoridazine.
EthanolMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Mesoridazine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mesoridazine.
EthosuximideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethyl loflazepate.
EthylmorphineMesoridazine may increase the hypotensive activities of Ethylmorphine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Mesoridazine.
EtidocaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Mesoridazine.
EtoperidoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Etoperidone.
EtorphineMesoridazine may increase the hypotensive activities of Etorphine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Mesoridazine.
EzogabineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fenfluramine.
FentanylMesoridazine may increase the hypotensive activities of Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mesoridazine.
FexofenadineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Mesoridazine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Mesoridazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Mesoridazine.
FluspirileneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Mesoridazine.
GabapentinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Mesoridazine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Mesoridazine.
HalofantrineThe serum concentration of Mesoridazine can be increased when it is combined with Halofantrine.
HaloperidolThe metabolism of Mesoridazine can be decreased when combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Halothane.
HeroinMesoridazine may increase the hypotensive activities of Heroin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Mesoridazine.
HexobarbitalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Hexobarbital.
HydrocodoneMesoridazine may increase the hypotensive activities of Hydrocodone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Mesoridazine.
HydromorphoneMesoridazine may increase the hypotensive activities of Hydromorphone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Mesoridazine.
Hydroxyamphetamine hydrobromideMesoridazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxychloroquineThe serum concentration of Mesoridazine can be increased when it is combined with Hydroxychloroquine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.
HydroxyzineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Mesoridazine.
IndalpineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Indalpine.
IndenololMesoridazine may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Mesoridazine can be decreased when combined with Indinavir.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Mesoridazine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Mesoridazine.
IsoniazidThe metabolism of Mesoridazine can be decreased when combined with Isoniazid.
KetamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ketazolam.
KetobemidoneMesoridazine may increase the hypotensive activities of Ketobemidone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Mesoridazine.
KetoconazoleThe metabolism of Mesoridazine can be decreased when combined with Ketoconazole.
LabetalolMesoridazine may increase the hypotensive activities of Labetalol.
LamotrigineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levetiracetam.
LevobunololMesoridazine may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levodopa.
Levomethadyl AcetateMesoridazine may increase the hypotensive activities of Levomethadyl Acetate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Mesoridazine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levomilnacipran.
LevorphanolMesoridazine may increase the hypotensive activities of Levorphanol.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mesoridazine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Mesoridazine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Mesoridazine.
LisdexamfetamineMesoridazine may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Mesoridazine.
LithiumThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Lithium.
LofentanilMesoridazine may increase the hypotensive activities of Lofentanil.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Mesoridazine.
LopinavirThe metabolism of Mesoridazine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Mesoridazine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Mesoridazine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Mesoridazine.
Lu AA21004The risk or severity of adverse effects can be increased when Mesoridazine is combined with Lu AA21004.
LumefantrineThe serum concentration of Mesoridazine can be increased when it is combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Lurasidone.
MagaldrateMagaldrate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Magnesium Sulfate.
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Mesoridazine.
MeclizineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Medetomidine.
MefloquineThe serum concentration of Mesoridazine can be increased when it is combined with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Melperone.
MephentermineMesoridazine may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Mesoridazine.
MequitazineMesoridazine may increase the arrhythmogenic activities of Mequitazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Metaxalone.
MethadoneMesoridazine may increase the hypotensive activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Mesoridazine.
Methadyl AcetateMesoridazine may increase the hypotensive activities of Methadyl Acetate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Mesoridazine.
MethamphetamineMesoridazine may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Mesoridazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Mesoridazine.
MetipranololMesoridazine may increase the hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Mesoridazine.
MetoprololMesoridazine may increase the hypotensive activities of Metoprolol.
MetoprololThe metabolism of Mesoridazine can be decreased when combined with Metoprolol.
MetyrosineMesoridazine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Mesoridazine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Mesoridazine.
MilnacipranThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.
MirabegronThe metabolism of Mesoridazine can be decreased when combined with Mirabegron.
MirtazapineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Mesoridazine.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Mesoridazine.
MolindoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Molindone.
MorphineMesoridazine may increase the hypotensive activities of Morphine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Mesoridazine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.
NabiloneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Nabilone.
NadololMesoridazine may increase the hypotensive activities of Nadolol.
NalbuphineMesoridazine may increase the hypotensive activities of Nalbuphine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mesoridazine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Mesoridazine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Mesoridazine.
NevirapineThe metabolism of Mesoridazine can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Mesoridazine can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Mesoridazine can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Nitrous oxide.
NormethadoneMesoridazine may increase the hypotensive activities of Normethadone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Mesoridazine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Mesoridazine.
OlanzapineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Mesoridazine.
OpiumMesoridazine may increase the hypotensive activities of Opium.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Mesoridazine.
OrphenadrineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Mesoridazine.
OsanetantThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Mesoridazine.
OxprenololMesoridazine may increase the hypotensive activities of Oxprenolol.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Mesoridazine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Mesoridazine.
OxycodoneMesoridazine may increase the hypotensive activities of Oxycodone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mesoridazine.
OxymorphoneMesoridazine may increase the hypotensive activities of Oxymorphone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Mesoridazine.
PaliperidoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Paliperidone.
PanobinostatThe metabolism of Mesoridazine can be decreased when combined with Panobinostat.
ParaldehydeMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Mesoridazine.
ParoxetineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Mesoridazine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololMesoridazine may increase the hypotensive activities of Penbutolol.
PentazocineMesoridazine may increase the hypotensive activities of Pentazocine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mesoridazine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Mesoridazine.
PerampanelThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Mesoridazine.
PethidineMesoridazine may increase the hypotensive activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Mesoridazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Mesoridazine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Phenoxyethanol.
PhentermineMesoridazine may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pimozide.
PindololMesoridazine may increase the hypotensive activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pomalidomide.
PractololMesoridazine may increase the hypotensive activities of Practolol.
PramipexoleMesoridazine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Mesoridazine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Mesoridazine.
PrimaquineThe serum concentration of Mesoridazine can be increased when it is combined with Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Mesoridazine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Mesoridazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mesoridazine.
ProguanilThe serum concentration of Mesoridazine can be increased when it is combined with Proguanil.
PromazineThe metabolism of Mesoridazine can be decreased when combined with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Mesoridazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Mesoridazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Mesoridazine.
PropoxycaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Propoxycaine.
PropranololMesoridazine may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Mesoridazine.
PSD502The risk or severity of adverse effects can be increased when Mesoridazine is combined with PSD502.
PyrimethamineThe serum concentration of Mesoridazine can be increased when it is combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Quetiapine.
QuinacrineThe serum concentration of Mesoridazine can be increased when it is combined with Quinacrine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Mesoridazine.
QuinidineThe serum concentration of Mesoridazine can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Mesoridazine can be increased when it is combined with Quinine.
RadicicolThe serum concentration of Mesoridazine can be increased when it is combined with Radicicol.
RamelteonThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ramelteon.
RanolazineThe metabolism of Mesoridazine can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Mesoridazine.
RemifentanilMesoridazine may increase the hypotensive activities of Remifentanil.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mesoridazine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Mesoridazine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Mesoridazine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Mesoridazine.
RitonavirThe metabolism of Mesoridazine can be decreased when combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Mesoridazine.
RolapitantThe metabolism of Mesoridazine can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Romifidine.
RopiniroleMesoridazine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Mesoridazine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Mesoridazine.
RotigotineMesoridazine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Mesoridazine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Mesoridazine is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Mesoridazine.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Mesoridazine.
SertindoleThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Sevoflurane.
SinefunginThe serum concentration of Mesoridazine can be increased when it is combined with Sinefungin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Sodium oxybate.
SotalolMesoridazine may increase the hypotensive activities of Sotalol.
StiripentolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Stiripentol.
SufentanilMesoridazine may increase the hypotensive activities of Sufentanil.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mesoridazine.
SulfadoxineThe serum concentration of Mesoridazine can be increased when it is combined with Sulfadoxine.
SulfametopyrazineThe serum concentration of Mesoridazine can be increased when it is combined with Sulfametopyrazine.
SulpirideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Mesoridazine.
SuvorexantThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Suvorexant.
tafenoquineThe serum concentration of Mesoridazine can be increased when it is combined with tafenoquine.
TapentadolMesoridazine may increase the hypotensive activities of Tapentadol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Mesoridazine.
TasimelteonThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Mesoridazine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Mesoridazine.
TerbinafineThe metabolism of Mesoridazine can be decreased when combined with Terbinafine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Mesoridazine.
TetracaineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tetrodotoxin.
ThalidomideMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Mesoridazine.
ThiamylalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Mesoridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tiagabine.
TiclopidineThe metabolism of Mesoridazine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tiletamine.
TimololMesoridazine may increase the hypotensive activities of Timolol.
TipranavirThe metabolism of Mesoridazine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Topiramate.
TramadolMesoridazine may increase the hypotensive activities of Tramadol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Mesoridazine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mesoridazine.
TrazodoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Mesoridazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Mesoridazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Mesoridazine.
TrimethoprimThe serum concentration of Mesoridazine can be increased when it is combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Mesoridazine.
TriprolidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Mesoridazine.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Mesoridazine.
VigabatrinThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zimelidine.
ZiprasidoneThe metabolism of Mesoridazine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Mesoridazine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Mesoridazine.
ZonisamideThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zuclopenthixol.
Food Interactions
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR: Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther. 2005 Dec;315(3):1278-87. Epub 2005 Aug 31. [PubMed:16135699 ]
  3. Choi S, Haggart D, Toll L, Cuny GD: Synthesis, receptor binding and functional studies of mesoridazine stereoisomers. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4379-82. [PubMed:15357957 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Choi S, Haggart D, Toll L, Cuny GD: Synthesis, receptor binding and functional studies of mesoridazine stereoisomers. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4379-82. [PubMed:15357957 ]
  2. Rauser L, Savage JE, Meltzer HY, Roth BL: Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther. 2001 Oct;299(1):83-9. [PubMed:11561066 ]
  3. Herrick-Davis K, Grinde E, Teitler M: Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther. 2000 Oct;295(1):226-32. [PubMed:10991983 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23